GDUFA Performance Goals For Fiscal Years 2013-2017
Executive Summary
By the end of the user fee cycle in FY 2017, FDA expects to have cleared the backlog and be acting on un-amended ANDA submissions with 10 months.
You may also be interested in...
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.
'Bridging' Of Generic Review Goal Dates Makes Progress At US FDA
Assigning official goal dates to ANDAs that hadn't been included in GDUFA began in mid-October and already has lead to approvals.